Kenya

Status: affected by circulating vaccine-derived poliovirus

Polio this week in Horn of Africa

  • No circulating vaccine-derived poliovirus type 2 (cVDPV2) cases were reported in the past week.
  • The Horn of Africa is currently affected by separate outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2) and type 3 (cVDPV3), reporting both AFP cases and environmental positive samples.
  • Somalia has reported a total of 12 cVDPV cases (five type 2, six type 3 and one, coinfection of both type 2 and type 3) in 2018.
  • The most recent cVDPV2 virus was isolated from an environmental sample collected on 11 October 2018 from Waberi district in Banadir province.  The most recent cVDPV3 virus was isolated from an environmental sample also from Waberi district, Banadir province collected on 23 August 2018.
  • Circulating VDPV2 has also been detected during 2018 in one environmental sample in Kenya collected on 21 March 2018.
  • Outbreak response to both virus types is currently being implemented in line with internationally-agreed guidelines. Large-scale supplementary immunization activities (SIAs) have been implemented in Banadir, Lower Shabelle and Middle Shabelle regions, Somalia.
  • WHO and partners continue to support local public health authorities across the Horn of Africa in conducting field investigations and risk assessments.
  • Read our Somalia country page and Kenya country page to see information on surveillance and vaccination campaigns.
  • Learn more about vaccine-derived polioviruses through this short animation or this ‘Coffee with Polio Experts’

International Health Regulations

Kenya is classified by the International Health Regulations (IHR) as a state infected with cVDPV2, with potential risk of international spread. It is therefore subject to temporary recommendations as of February 2019

Travel advice

WHO’s International Travel and Health recommends that all travellers to polio-affected areas be fully vaccinated against polio. Residents (and visitors for more than 4 weeks) from infected areas should receive an additional dose of OPV or inactivated polio vaccine (IPV) within 4 weeks to 12 months of travel.

More on vaccine-derived polioviruses